



BIOSCIENCE DISCOVERY EVALUATION GRANT PROGRAM
For Proof of Concept Projects
2008-2009 Program
(RULES AND APPLICATION)

CONTENTS

Program Overview	Page 2
Application and Review Schedule	2
Statutory Authority	2
Eligibility	2
Grant Awards	3
Application Review	5
Confidentiality and Open Records	6
Reporting Requirements	7
Audits	8
Application	8
Certifications	11

AGENCY CONTACT

Sonya Guram, Bioscience Programs Manager

Or Alice Kotrlik, Deputy Director

Phone: 303-892-3840

E-mail: sonya.guram@state.co.us

Business Finance Division

Colorado Office of Economic Development and International Trade

1625 Broadway, Suite 2700. Denver, Colorado 80202

Fax: 303-892-3848

TDD: 1-800-659-2656

Website: www.AdvanceColorado.com

I. PROGRAM OVERVIEW

The Proof-of-Concept grants under the Bioscience Discovery Evaluation Grant Program (BDEGP) are intended to support bioscience discoveries that will likely lead to the development of new products, services, businesses and employment in the bioscience industry in Colorado. Grants up to \$150,000 will be accessible to Offices of Technology Transfer (OTT) affiliated with qualified Research Institutions in order to enhance the commercial potential of bioscience research projects that focus on life sciences, engineering, material sciences computer sciences, photonics, or nanotechnology.

II. APPLICATION AND REVIEW SCHEDULE

OEDIT has established the following application deadline and review/decision schedule:

OEDIT Application Deadline	Grant Decisions
<i>First Cycle:</i> November 15, 2008	December 31, 2008
<i>Second Cycle:</i> April 15, 2009	May 30, 2009

Funds not awarded in these cycles will be available for Proof-of-Concept grants in the next fiscal year.

III. STATUTORY AUTHORITY

The Bioscience Discovery Evaluation Grant Program (BDEGP or Program), pursuant to C.R.S. 24-48.5-108 and 12-47.1-701, was established by the Colorado legislature to supply needed resources for improving and accelerating the evaluation process for bioscience research discoveries, to determine the best disposition of these discoveries, and to accelerate viable technologies toward commercialization. The legislature declared that it is in the best interests of the state's economic growth to dedicate financial resources to facilitate the development of new bioscience research discoveries in Colorado and promote Colorado-based bioscience technologies that will ultimately create new bioscience companies and additional primary jobs in Colorado.

IV. ELIGIBILITY

Proof-of-Concept grants are available to Offices of Technology Transfer at eligible Research Institutions. The proposed project must focus on life sciences, engineering, material sciences, computer sciences, photonics, or nanotechnology.

Research Institution means an institution located and operating in Colorado that is a public or private, nonprofit institution of higher education, a nonprofit teaching hospital, or a private, nonprofit medical and research center. For-profit entities are not eligible for the Program.

Office of Technology Transfer means an office that is affiliated with a research institution and that is charged with the responsibility for technology transfer and that arranges for the sale or licensure of a bioscience research project to an outside entity, which is commonly a commercial enterprise.

Eligible Research Institutions with established Offices of Technology Transfer are:

Institution	Office	Contact	Phone	e-mail
Bonfils Blood Center	Technology Transfer	Daniel R. Ambruso, MD	303-341-4000	daniel_ambruso@bonfils.org
Children's Hospital Research Institute Colorado School of Mines	CU Technology Transfer Office Technology Transfer	David Allen	303-735-3711 303-384-2470	david.allen@cu.edu
Colorado State University	CSU Research Foundation Technology Transfer Office	Todd Headley	970-482-2916	todd.headley@csurf.colostate.edu
National Jewish Health	Intellectual Property and Technology Commercialization	Emmanuel Hilaire, Ph. D.	303-398-1262	hilairee@njc.org
University of Colorado (Boulder, Colorado Springs, Denver, HSC)	CU Technology Transfer Office	David Allen	303-735-3711	david.allen@cu.edu
University of Colorado Hospital	CU Technology Transfer Office	David Allen	303-735-3711	david.allen@cu.edu
University of Denver	Intellectual Property and Technology Transfer Office	Stephen A. Hall	303-871-4937	stephen.hall@du.edu
University of Northern Colorado	Graduate School & Technology Transfer	Robbyn R. Wacker, Ph.D.	970-351-1808	robyn.wacker@unco.edu

Bioscience Research means the study of biological processes, organisms, devices, diagnostics, or systems with the objective of developing products that are intended to improve agriculture, the quality of human life, or the environment. “Bioscience Research” includes, but is not limited to, biofuel research and life sciences research.

Biofuel Research means the use of microorganisms, specialized proteins, or thermal processes to develop biologically based fuel products from plant matter or other biological material, including renewable agricultural sources, and the related processes that make traditional manufacturing of energy cleaner and more efficient.

Any intellectual property (IP) developed at the time of application that will be further developed or commercialized under the grant project, may not be obligated to a private entity other than the associated OTT. IP may be obligated after a fully executed Grant Agreement with OEDIT is in place.

V. GRANT AWARDS

The Bioscience Discovery Evaluation Cash Fund has been established to hold monies and provide grant awards for the BDEGP. For fiscal year 2008-09, \$1,567,500 is allocated for Proof-of-Concept Grants.

A. ALLOCATION

A preliminary allocation of grant-funds has been made to eligible institutions as follows:

Research Institution	FY 2008-09	
	%	Dollar Amount
Bonfils Blood Center Colorado School of Mines University of Denver University of Northern Colorado	15%	235,125
Colorado Institute for Molecular Biology	19.1%	300,000
Colorado State University	22.5%	352,688
National Jewish Health	10%	156,750
University of Colorado	33.4%	522,938
TOTAL		\$1,567,500

In determining which research institution's pool of funds to draw from for grant awards, the employment/affiliation of the lead researcher and ownership of intellectual property will be taken into account.

B. GRANT MAXIMUM

1. Proof-of-Concept projects can receive a **maximum grant of \$150,000**.
2. The Bioscience Discovery Evaluation Grant Committee (BDEGC) may recommend a grant for an amount other than that requested in the application. Final decisions will be made by the Executive Director of OEDIT.
3. All grants are awarded to OTTs at qualified Research Institutions who will distribute the grant to the specific approved project.

C. ELIGIBLE COSTS

Costs eligible to be paid under the program may only be incurred after the effective date of a legal agreement executed with OEDIT.

1. **Direct Costs** are related to specific time and effort and are readily and specifically identifiable with the bioscience research project. Direct costs include market analysis, qualified consultants (such as clinical consultants), analytical or laboratory work (such as prototype/product design, toxicology, manufacturability), documented direct time worked on project (such as investigator time), leased equipment, and direct lab supplies (consumables). Costs related to intellectual property (IP), Freedom to Operate analyses, travel expenses and equipment purchases are generally not eligible. Any other costs must be considered/approved on a case-by-case basis. Documentation of these expenses including invoices of actual expenses should be maintained.
2. **Indirect Costs**, also known as Indirect Cost Recovery, are those incurred for common or joint objectives. They are not readily and specifically identified with a specific bioscience research project. Indirect costs payable with grant funds are limited to **8%** of the

project's total direct costs. An OTT must charge indirect costs to matching funds at the same rate and in the same amount as they are charged to Program funds.

D. MATCHING FUNDS

Applicants must have matching funds secured at the time of application. At least a **1:1 match** of the grant requested is required. An OTT may use interest earned by the OTT on BDEGP funds to pay for eligible project costs; however, such interest is not considered matching funds.

E. PAYMENTS

Grant participants shall be compensated for eligible costs incurred for performance of the project plan. Awards will generally be disbursed based on an advance payment basis; however, payments may be disbursed in tranches and/or an appropriate retainer may be held until completion of the project/Agreement as determined by OEDIT.

F. LEGAL AGREEMENTS WITH OEDIT

OTTs will need to have a Grant Agreement executed with OEDIT prior to proceeding with any aspect of the bioscience research project including the expenditure of state and matching funds.

G. BUDGET ADJUSTMENTS

1. OEDIT acknowledges that the costs outlined in the Application budget are estimates. Therefore, a Grantee may shift funds between the line-items associated with each budget category, unless indicated otherwise in the Grant Agreement. For example, line items might be specific personnel within a Personnel & Labor category. The aggregate amount for each category of costs as set forth in the Project Budget should not be exceeded. Pre-approval for shifts within an expense category are not required; however, the grantee will need to identify such shifts in annual reports.
2. Additionally a Grantee may, shift funds between categories of expense, up to 10% of any one category, without pre-approval. Again, the grantee will need to identify such shifts in its annual reports. For larger shifts of funds between categories, the grantee must first seek approval from OEDIT.

H. RETURN OF UNUSED GRANT MONEY

Upon completion of a bioscience research project or within 60 days of early-termination of a project by the OTT's choice, any unused grant money shall be returned by the OTT to OEDIT. The funds will be de-obligated and returned to the Bioscience Discovery Evaluation Cash Fund.

VI. APPLICATION REVIEW

Given the allocation of funds among eligible research institutions, those institutions with a specific allocation will be required to conduct an internal review as outlined below, and may submit proposals via their OTTs totaling the dollar amount for which they are eligible. The four institutions in a pool for 15% of the total funds may submit all eligible applications to OEDIT for selection by the Bioscience Discovery Evaluation Grant Committee. See the Allocations under the Grant Awards section of this document for clarification on which process should be followed. OEDIT will review all applications for compliance with the rules outlined in this document before any grants are awarded. The amounts allocated will be available to those institutions for both the first and second grant cycles.

A. OTT REVIEW

Each OTT shall develop an internal review and selection process for applications to be forwarded to OEDIT. The review shall place specific emphasis on improving and accelerating the evaluation process for bioscience research discoveries, to determine the best disposition of these discoveries, and accelerate viable technologies toward commercialization. The review should favor projects that will ultimately create new bioscience companies and additional primary jobs in Colorado. The OTT's internal review committee shall be comprised of OTT, research institution, and private bioscience industry representation. Documentation of this process will be submitted to OEDIT.

B. BDEGC REVIEW

1. The \$235,125 in Proof-of-Concept grant funds is available to Bonfils Blood Center, Colorado School of Mines, the University of Denver, and the University of Northern Colorado on a competitive basis. OEDIT shall convene a Bioscience Discovery Evaluation Grant Committee (BDEGC) comprised of industry experts as well as Colorado Bioscience Association (CBSA) and OEDIT representatives to review, evaluate and make recommendations on these applications. All applications will be competitively evaluated by the BDEGC to focus on those that best advance the commercial potential of a bioscience discovery.
2. Applicants will be informed of the BDEGC meeting to consider their proposal, and are encouraged to attend.

VII. CONFIDENTIALITY AND OPEN RECORDS

OEDIT is subject to the Colorado Open Records laws (C.R.S. 24-72-101 through 24-72-112). Thus, documents and other materials received by OEDIT and its employees may be subject to public disclosure.

OEDIT will deny the right of inspection of records considered trade secrets, privileged information, and confidential commercial and financial data. Applicants should clearly mark areas of the application they consider to be trade secrets, privileged information, and confidential commercial and financial data. The entire application may not be marked "confidential". Please note that information considered confidential at the time of application may cease to be so at a later date.

Upon receiving an official open records request, OEDIT will immediately notify the applicant and as needed, seek legal guidance from the Office of the Attorney General for a ruling on confidential information. Applicants should be aware that OEDIT can only respond to requests to review records to the extent that such information is contained in OEDIT's files.

The applicant should also be aware that the Bioscience Discovery Evaluation Grant Committee (BDEGC), some of whom are not state employees, will receive and review the application documents. Committee members have agreed to lend their expertise and advice in reviewing grant applications, solely to benefit the public. Panel members agree to treat applications and panel discussions as confidential.

VIII. REPORTING REQUIREMENTS

A. ANNUAL PROGRESS REPORT

1. For each project receiving grant funds, the OTT must submit an annual report documenting the progress of the research and commercialization activity. OEDIT will provide a report outline for each project based on the milestones, deliverables and budget developed for the Statement of Work in the Grant Agreement. OTTs will report on results achieved, monetary and other returns associated with licensing the technology, companies and jobs created. The report will need to identify the use of grant and matching funds. A project financial report must be included. OEDIT will provide this outline to the OTT around February 1, but not later than February 15, each year that the project grant is open. The OTT must have the report completed and returned to OEDIT by March 15 in the same electronic format that the outline was given. If supporting documentation is not available in an electronic format, a hard-copy of the full report and supporting materials may be submitted to OEDIT along with the electronic copy of the report.
2. Additionally, the annual report will require follow-up reporting on closed or completed projects having received BDEGP grant funds. The follow-up reports will request the following information in order to evaluate the success of the state program in fostering development of Colorado's bioscience industry.
 - a) Status of IP – Was new IP developed? Has the IP been extended or obligated outside of the OTT or Research Institution? If so, provide details.
 - b) Technology Licensing – Has the technology been licensed outside of the RI? To whom?
 - c) Follow-on Capital Investment – Since the conclusion of the state Grant Award, what capital investment has this technology received?

B. EDUCATION PRESENTATION

At some point during the grant period, the grant recipient must present the research project to elementary and secondary school science teachers employed in the school district where the research is being developed. CBSA has worked with the OTTs to fulfill this requirement in past grant cycles, and may be available to coordinate this activity in the future. However, it is ultimately the responsibility of the grant recipient to make sure that this statutory requirement is fulfilled. The aim of this requirement is to provide relevant and interesting examples of scientific discovery for teachers and school children. The format of the required presentation is not set, and the grantee may develop its own creative approach to fulfilling this requirement. The grantee must discuss and coordinate its plans to fulfill the educational presentation with OEDIT. OEDIT's Bioscience Program Manager should be invited to attend any presentations. The grantee must report to OEDIT on its performance of this requirement upon fulfillment either in an Annual Progress Report or the Project End Report.

C. PROJECT END REPORT

This report is a similar format to the annual report, but is provided at the conclusion of a project/grant. The end report should document completion of all activities outlined in the Statement of Work. This report should include an analysis of the results and findings from the project efforts. Technical difficulties, errors, and planned or recommended next steps should be described. A project financial report identifying matching and grant funds must be included. An outline for this report will be sent by OEDIT at least one month before the project's end-date.

The report will be due to OEDIT within 90 days of the project's end-date, as identified in the formal Grant Agreement.

IX.

IX. AUDITS

A. OTT

Each OTT will be required to provide a copy of any OTT or Research Institution (RI) annual audit released during the term of the Agreement to OEDIT. For most OTTs, this requirement will mean a copy of the research institutions audit. For OTT's that are legally separate but affiliated with a research institution, the OTT will need to provide a copy of their annual audit.

B. PROJECT

The project itself, including the primary researcher and laboratory or research setting are subject to monitoring and audit for performance under a grant agreement. A grantee shall maintain a complete file of all records, documents, communications, notes and other written materials or electronic media, files or communications, which pertain in any manner to the operation of programs or activities undertaken pursuant to an executed Agreement. Such books and records shall contain documentation of the participant's pertinent activity under a Grant Agreement in a form consistent with good accounting practice.

X. APPLICATION

To be eligible for a grant under the program, Offices of Technology Transfer shall submit to OEDIT one original signed application, and by e-mail a Word or PDF file, for each bioscience research project. Such application(s) shall be submitted on or before the OEDIT Application Deadline (see page 2) in order to be considered in an application cycle. The application should follow this format.

A. IDENTIFYING INFORMATION

1. Name of Office of Technology Transfer & Associated Research Institution:
2. Contact Information for OTT:
3. Identify which OTT or Research Institution(s) owns the subject intellectual property:
4. Title of specific Bioscience Research Project
5. Name of Research Scientist:
6. Identify the Research Institution(s) that employ the Research Scientist:
7. Has this scientist received any other BDEGP grant? If so, give the BDEGP project name, dates, and award amount.
8. Check the box(es) that describe the field to which the project proposal relates
 - Human Health - therapeutic or diagnostic products, devices or instruments
 - Agriculture – bioscience technologies that improve agriculture
 - Biofuels – development of biologically based fuels
9. Requested Grant Amount (not to exceed \$150,000, excluding matching funds):

B. PROJECT NARRATIVE

1. Summary (*1 page or less in layman's terms, do not include any confidential information*)
Provide a brief summary of the proposed Project including a description of the scientific research and its merits. Describe the anticipated commercial potential, and the market segment that the developed technology will address. Will this product/service be a new offering? Does it improve upon existing offerings? Will it partner with existing products/services?

2. Project Plan (*3 pages or less in layman's terms*)
 - a) Describe the strategic objective of the project.
 - b) Articulate key objectives and specific aims of the project.
 - c) Explain how this project improves or accelerates the evaluation of the commercial potential of a new bioscience discovery.
 - d) Identify the technical questions that will be addressed by any research conducted as part of the project, and explain how addressing those questions will positively impact human health, agriculture, or the biofuels industry.
 - e) Describe the approach to the research, major elements of research design, and key features of the methodology.
 - f) Describe how the proposed project builds upon previous research that has been conducted by the applicant research institution and other institutions worldwide.
 - g) Identify problems that you might encounter in the proposed project and how you intend to manage and/or resolve them.
 - h) Identify any prior or current grants the investigator has to develop this technology, and explain plans for future grants.

3. Commercialization (*2 pages or less in layman's terms*)
 - a) Describe the anticipated market potential for the product or service that will ultimately be developed as a result of this project.
 - b) Identify the strengths, weaknesses, opportunities and threats of this technology in meeting a market need.
 - c) Identify any developed intellectual property to-date on this research.
 - d) Estimate the long-term outcomes of this project in terms of Colorado jobs and investment.

C. WORK PLAN

Drawing on the Project Narrative, identify specific project tasks/milestones on a timeline (and tie them to a budget where feasible). Make sure to identify project start and end dates in terms of months from an executed Grant Agreement.

D. BUDGET

1. Has the subject technology of this application received other grant funding?
If so, please provide grant source, amount, and scope of grant project.

2. Provide a project budget that supports the Work Plan above. Refer to the Eligible Cost information in the Grant Awards section of this document. The budget should include all anticipated project costs and identify Program grant and matching funds. Indirect costs that exceed the maximum amount allowed by the Program, should not be reflected in the budget - such items may be noted below the line if the applicant chooses to do so. Indirect costs exceeding the 8% allowed may not be considered part of the required match. Matching funds must meet or exceed the amount of grant funds requested.

This budget outline is provided for direction. Please include a reasonable level of detail for planned project expenditures.

		Source		
Direct Costs			BDEGP	Match
	Personnel & Labor	50,000	25,000	25,000
	Materials & Supplies	20,000	10,000	10,000
	Publication Cost	1,000	500	500
	Equipment Rental Fees	8,000	4,000	4,000
	Field Trials	6,000	3,000	3,000
Total Direct		85,000	42,500	42,500
Indirect Costs (8% max)		6,800	3,400	3,400
TOTAL		\$91,800	\$45,900	\$45,900

E. RESEARCHERS' BIOGRAPHICAL INFORMATION

Please attach curriculum vitae or a short narrative with relevant background and accomplishments for each of the key investigators and project developers.

F. OTT PROCESS (please limit to 1 page)

1. Application/Review Process. Describe or attach the OTT's process for application, review and selection including the committee decision-making process, and a list of the people and their functions that participated throughout the OTT review/approval process for this specific bioscience research project.

2. Provide a description of the OTT's conflict of interest policies/processes (either briefly describe or attach). Disclose any real or perceived conflicts of interest related to this specific bioscience research project.

*note: Should the OTT Review Process and/or the Conflict of Interest Policy be the same, the OTT need submit these documents only once for multiple project applications in a grant cycle. However, the applicant should be sure to make any disclosure related to conflict of interest for each project.

G. EDUCATIONAL OUTREACH

Describe your preliminary plans for fulfilling educational outreach to science teachers in your school district. See the Reporting Requirements section for information on this requirement.

OEDIT reserves the right to modify any of the rules here-in, so long as such modifications meet statutory criteria. Interested parties will be notified of any such modification.

XI. CERTIFICATIONS

The OTT certifies that:

- The bioscience research project described in this application and for which the OTT is requesting Program funds complies with the statutory criteria, rules and application requirements identified in this application document:
 - the bioscience research involves the use of biological processes, organisms, devices, diagnostics, or systems with the objective of developing products that are intended to improve agriculture, the quality of human life, or the environment;
 - the intellectual property resulting from the bioscience research project is not obligated to a private entity outside of the OTT;
 - the scope of the project is the scope required to enhance the commercialization of the technology in Colorado;
- The OTT has a dedicated, matching source of moneys that is equal to or greater than the amount applied for under the program.
- This application for funding from the Program complies with the statute (24-48.5-108 C.R.S.) and the Rules and Application Requirements herein, and issued by the Colorado Office of Economic Development and International Trade.
- The information contained in this Application, including all attachments and exhibits, are true and correct.
- The person's or persons' signature on these Certifications and Application are authorized to act on behalf of the OTT.

Name and Title

Name of OTT

Signature

Date